Larix Clinical Trials Planning and Management Services

Larix is a full-service CRO providing assistance in all aspects of clinical trials. With our extensive experience we help you plan and manage your trials, from trial design and trial management to feasibility, clinical monitoring, database design and data management, statistical analysis, medical writing, and pharmacovigilance.

Our full attention is on our customers’ goals within their projects and on their specific needs. This is achieved by constant focus on communication, pro-activity and quality, delivered on time.

Clinical research services for drug development and trial management

Our department of clinical research offers many years of experience in drug development and trial management. We provide expert services in all key areas of the drug development process, including:

  • Overall planning of drug development, e.g. trial design and synopsis writing
  • Pre-trial feasibility
  • Clinical trial management, including protocol writing and ongoing trial management
  • Clinical trial monitoring, including site selection and site initiation, ongoing monitoring, and site close-out
  • Medical writing: writing of regulatory documents including clinical trial reports, synopsis and investigator’s brochure; and proof-reading and editing
  • Medical advice / drug development advisors

We offer out-sourced consultants as well as providing services from the Larix premises.

Data management services for clinical trials

Our department of data management offers many years of experience in data management. We provide expert services in all key areas of the data management process, including:

  • Input to trial protocol
  • Data management plans
  • CRF design and annotation
  • Database design
  • Validation planning and validation checks
  • Query process
  • Coding (adverse events, diseases and medication)
  • Database release and transfer of data
  • Final data management reports and delivery of all data to sponsors

Our data management services are based on the eDM system from Omnicomm. The system is fully 21CRF part 11 compliant and validated to relevant standards. We can also work with our sponsors’ own data management systems, e.g. Oracle Clinical.

Statistics services for clinical trials

Our department of statistics offers many years of experience in handling all statistical tasks, all the way from clinical pharmacology trials to pivotal phase III trials and beyond, including:

  • Input to trial protocol and statistical analysis planning
  • Choice of trial design and power calculations
  • Statistical programming and validation
  • Statistical analysis planning
  • The actual statistical analyses
  • Separate statistical reports or input to integrated reports
  • Interim analyses and meta-analyses, etc.
  • Statistical input to publications
  • Statistical support to regulatory issues, meetings, etc.

We also offer statistical services in non-clinical areas such as research and development laboratories, as well as statistical process control and statistics in production facilities.

About Larix

Larix is a CRO with a professional staff of around 20 people, located near Copenhagen. We have a range of customers from within and outside of this area. With more than eight years of experience we have provided services to small and large pharmaceutical companies and to a number of biotech and device companies. We are the largest CRO unit in Denmark in the areas of data management and statistics.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Larix aps

Tempovej 44

2750 Ballerup



+45 70 27 22 21 +45 70 27 22 41

Larix Images

Products and Services


White Papers

Related Projects

Afinitor Disperz (everolimus) for the Treatment of TSC-Associated Partial-Onset Seizures

Afinitor Disperz® (everolimus) is indicated for the treatment of tuberous sclerosis complex (TSC) associated partial-onset seizures in adult and paediatric patients.

14 June 2018

Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia

Doptelet® (avatrombopag) is one of the first thrombopoietin (TPO) receptor agonists to be approved in the US for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD).

5 June 2018

Herzuma (trastuzumab biosimilar) for the Treatment of Breast and Gastric Cancers

Herzuma® (trastuzumab biosimilar / CT-P6) is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer.

20 February 2018

Bavencio (avelumab) for the Treatment of Metastatic Merkel Cell Carcinoma

Bavencio® (avelumab) is a human PD-L1 monoclonal antibody indicated for the treatment of metastatic Merkel-cell carcinoma (MCC).

16 January 2018

Admelog (insulin lispro) for the Treatment of Type 1 and Type 2 Diabetes

Admelog® (insulin lispro) is a rapid-acting human insulin analogue approved as a follow-on product to treat type 1 and type 2 diabetes in adults and paediatric patients aged three years and older.

20 December 2017

KamRAB/KedRAB (rabies immunoglobulin human) for the Treatment of Rabies

KamRAB/KedRAB™ is a human rabies immunoglobulin (HRIG) indicated for the treatment of passive, transient post-exposure prophylaxis (PEP) of rabies infection. The drug was jointly developed by Kamada and Kedrion Biopharma.

7 September 2017

Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)

Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML).

17 August 2017

Haegarda for the Preventive Treatment of Hereditary Angioedema

Haegarda® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients.

12 July 2017

Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Radicava™ (edaravone) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS).

14 May 2017

Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis

Rydapt® (midostaurin) is a multi-targeted inhibitor of multiple kinases including FMS-like tyrosine kinase 3 mutation-positive (FLT3+) and KIT approved for the treatment of acute myeloid leukaemia (AML) and three types of advanced systemic mastocytosis (SM) indications.

2 May 2017

Press Release

Regional Offices

Larix aps

Tempovej 44

2750 Ballerup



Klaus Juel Olsen (CEO and head of statistics) +45 70 27 22 21 +45 70 27 22 41

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.